Impact of HMG-CoA Reductase in Breast Cancer
Author Information
Author(s): Signe Borgquist, Annika Jögi, Fredrik Pontén, Lisa Rydén, Donal J Brennan, Karin Jirström
Primary Institution: Malmö University Hospital, Lund University
Hypothesis
The study examines the prognostic value of HMG-CoA reductase expression in primary breast cancer patients.
Conclusion
HMG-CoA reductase expression is an independent predictor of prolonged recurrence-free survival in primary breast cancer, particularly in ER-positive tumors.
Supporting Evidence
- HMG-CoA reductase expression was associated with low grade tumors (p < 0.001).
- Patients with HMG-CoA positive tumors had a significantly prolonged recurrence-free survival (RR = 0.60, p = 0.002).
- In ER-positive tumors, HMG-CoA expression was linked to improved outcomes (p < 0.0001).
- No significant association was found between HMG-CoA expression and ER-negative tumors.
Takeaway
This study found that a specific protein in breast cancer cells can help predict how long patients will stay cancer-free after treatment, especially for those with a certain type of cancer.
Methodology
HMG-CoA reductase expression was assessed using immunohistochemistry on tissue microarrays from 498 breast cancer cases, with survival analyzed using Kaplan-Meier and Cox models.
Limitations
The study's findings may not apply to ER-negative tumors, and the small number of ER-negative cases limits the conclusions that can be drawn.
Participant Demographics
Median age at diagnosis was 65 years, with a range from 27 to 96 years.
Statistical Information
P-Value
p = 0.002
Confidence Interval
95% CI 0.40 to 0.92
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website